Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver Doxorubicin in Unprecedented Concentrations Directly into a Targeted Tumor  Comments on Common Stock

Company to Provide Clinical Development Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a

GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring Board

The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis. The Pooled Progression-Free Survival (PFS) Data is Consistent with What Was Observed in the Pooled HEAT Study Subgroup Data.

  $2 Million in Additional NOL Sales are Available to the Company in 2020 Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today

LAWRENCEVILLE, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces that Michael Tardugno , Chairman, President and Chief Executive Officer and Khursheed Anwer , Executive Vice President and Chief Scientific Officer will

LAWRENCEVILLE, N.J. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the recent 13 th Annual Conference of the International Liver Cancer Association

Data show overall survival improvement of 22.5 months with ThermoDox ® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox’s potential for superior efficacy when combined with a well-executed RFA procedure LAWRENCEVILLE, N.J , Aug.

     First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New Jersey State Net Operating Losses Will Fund Operations Into 2021 NIH Manuscript Provides Support for ThermoDox’s Potential in the

NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox ® Improves Overall Survival with Significance in Patients with Primary Liver Cancer NIH Analysis Supports the OPTIMA Study Design, Celsion’s Fully Enrolled Global